SutroVax picks up $85 million in Series C round for pneumococcal vaccine
SutroVax, spun off from Sutro Biopharma, also announced a contract manufacturing deal with Swiss vendor Lonza.
SutroVax nets $22M Series A for conjugate vaccine work
Bay Area startup SutroVax just raised $22 million for work in developing conjugate vaccines - and likely improving upon existing inoculations for pneumococcal conditions.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.